Brian Druker Explained

Brian J. Druker
Birth Date:April 30, 1955
Birth Place:St. Paul, Minnesota
Nationality:American
Fields:Oncology
Workplaces:Howard Hughes Medical Institute, Oregon Health & Science University
Alma Mater:University of California, San Diego, Washington University School of Medicine
Known For:Gleevec

Brian J. Druker (born April 30, 1955)[1] is a physician-scientist at Oregon Health & Science University (OHSU), in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute,[2] [3] JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.[4]

Druker helped develop imatinib (Gleevec), the first medication that specifically targets cancer cells, for the treatment of chronic myeloid leukemia (CML).[5] [6] [7] In 2001, Gleevec gained FDA approval in record time[8] and landed on the cover of Time magazine.[9] Druker’s work launched the era of precision cancer medicine, setting the stage for future discoveries in the quest to end cancer.[10]

He is the recipient of the 2009 Lasker-DeBakey Clinical Medical Research Award,[11] the 2012 Japan Prize in Healthcare and Medical Technology,[12] the 2013 Albany Medical Center Prize in Medicine and Biomedical Research,[13] and the 2019 Sjöberg Prize,[14] among others. He has been called "Oregon's best-known scientist".[15]

Education

Druker earned both his B.A. degree in chemistry and M.D. degree from the University of California, San Diego.[16] He completed his internship and residency in internal medicine at Barnes Hospital, Washington University School of Medicine in St. Louis from 1981 to 1984.[17]

Teaching and Research

Druker was a fellow in medical oncology at Dana–Farber Cancer Institute at Harvard Medical School from 1984 to 1987. He began working at Oregon Health & Science University (OHSU) in 1993.[18]

In May 2007, he became director of the OHSU Cancer Institute—renamed the Knight Cancer Institute in October 2008 following a $100 million donation from Nike co-founder Phil Knight.[19]

Druker's research is focused on translating the knowledge of the molecular pathogenesis of cancer into specific therapies and investigating the optimal use of these molecularly targeted agents. He performed preclinical studies that led to the development of imatinib (Gleevec) for chronic myeloid leukemia (CML) and then spearheaded the highly successful clinical trials of imatinib, which led to FDA approval of the drug in record time. This work changed the life expectancy of patients with CML from an average of 3 to 5 years to a 89% five-year survival,[20] [21] and has resulted in a paradigm-shift in cancer treatment from non-specific chemotherapy to highly targeted therapeutic agents.[22] Druker has been widely recognized for his work in developing Gleevec, but has been publicly critical of the drug's high price for patients.[23] [24]

In 2015, Druker celebrated the completion of the Knight Cancer Challenge, raising $1 billion for research at the Knight Cancer Institute.[25] The Oregon Legislature and more than 10,000 donors from Oregon and beyond matched a $500 million grant from Phil and Penny Knight. The challenge gave the institute the funding to launch the Cancer Early Detection Advanced Research Center.

Druker also helped lead a national clinical trial to find effective treatments for acute myeloid leukemia (AML). The Beat AML clinical trial, sponsored by the Leukemia & Lymphoma Society (LLS), is a joint effort by medical centers, drug makers and the Food and Drug Administration.[26]

Memberships and awards

Druker was an investigator of Howard Hughes Medical Institute (HHMI) from 2002 to 2019. He was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2003 and the National Academy of Sciences in 2007. He is a member of the American Society for Clinical Investigation, Association of American Physicians, American Academy of Arts and Sciences, American Association for the Advancement of Science, American Society of Hematology, American Society for Microbiology, American Society of Clinical Oncology, American Association for Cancer Research, Children’s Oncology Group, and The American Society for Cell Biology. Druker has received the following awards, among others:[27]

Personal

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children (as of 2009). An earlier marriage, to Barbara Rodriguez in 1990, ended in divorce in 1999.[16]

External links

Notes and References

  1. Web site: Meyenburg Award 2009 for the First Targeted Anti-Cancer Drug. October 12, 2009. German Cancer Research Center. 2015-12-27.
  2. News: Terry. Lynne. OHSU's $1 billion war on cancer. 2015-12-27. The Oregonian. Portland, Oregon. December 20, 2015. online date December 17. A1, A12–A13.
  3. Web site: Meet Dr. Brian Druker Knight Cancer Institute OHSU . 2023-10-13 . www.ohsu.edu.
  4. Web site: Brian J. Druker M.D. OHSU People OHSU . 2023-10-13 . www.ohsu.edu.
  5. Druker . B. J. . Tamura . S. . Buchdunger . E. . Ohno . S. . Segal . G. M. . Fanning . S. . Zimmermann . J. . Lydon . N. B. . May 1996 . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells . Nature Medicine . 2 . 5 . 561–566 . 10.1038/nm0596-561 . 1078-8956 . 8616716. 36102747 .
  6. Druker . B. J. . Talpaz . M. . Resta . D. J. . Peng . B. . Buchdunger . E. . Ford . J. M. . Lydon . N. B. . Kantarjian . H. . Capdeville . R. . Ohno-Jones . S. . Sawyers . C. L. . 2001-04-05 . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia . The New England Journal of Medicine . 344 . 14 . 1031–1037 . 10.1056/NEJM200104053441401 . 0028-4793 . 11287972. free .
  7. O'Brien . Stephen G. . Guilhot . François . Larson . Richard A. . Gathmann . Insa . Baccarani . Michele . Cervantes . Francisco . Cornelissen . Jan J. . Fischer . Thomas . Hochhaus . Andreas . Hughes . Timothy . Lechner . Klaus . Nielsen . Johan L. . Rousselot . Philippe . Reiffers . Josy . Saglio . Giuseppe . 2003-03-13 . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia . The New England Journal of Medicine . 348 . 11 . 994–1004 . 10.1056/NEJMoa022457 . 1533-4406 . 12637609. free .
  8. News: Dreifus . Claudia . 2009-11-02 . Researcher Behind the Drug Gleevec . en-US . The New York Times . 2023-10-13 . 0362-4331.
  9. Web site: TIME Magazine Cover: Drugs That Fight Cancer - May 28, 2001 . 2023-10-13 . TIME.com . en-us.
  10. Web site: May 7, 2021 . OHSU marks 20 years of life-saving cancer drug . 2023-10-13 . kgw.com . en-US.
  11. Web site: Strauss. Evelyn. 2009 Winners: Lasker~DeBakey Clinical Medical Research Award . Lasker Foundation. 2015-12-27.
  12. Web site: The Japan Prize Foundation . 2023-10-13 . The Japan Prize Foundation . en.
  13. Web site: The Albany Prize . 2023-10-13 . Albany Med Health System . en-US.
  14. Web site: 2019-02-04 . Targeted treatment of cancer receives the Sjöberg Prize . 2023-10-13 . Kungl. Vetenskapsakademien . en-GB.
  15. News: How OHSU's Brian Druker Hopes to Cure Cancer. 2015-12-27. Willamette Week. Portland, Oregon. January 16, 2014.
  16. News: Charles. Nick. The Miracle Worker: Dr. Brian Druker Fires a Magic Bullet That May Eliminate a Lethal Form of Leukemia. 2015-12-27. People. February 19, 2001.
  17. Web site: Brian J. Druker . 2023-10-13 . Commencement Archive 2014-2019 . en-US.
  18. Five to receive honorary degrees at 149th Commencement. Washington University in St. Louis. 2015-12-27. May 6, 2010.
  19. News: Dworkin. Andy. OHSU Cancer Institute gets $100 million donation. 2015-12-27. The Oregonian. Portland, Oregon. October 29, 2008.
  20. Druker . Brian J. . Guilhot . François . O'Brien . Stephen G. . Gathmann . Insa . Kantarjian . Hagop . Gattermann . Norbert . Deininger . Michael W.N. . Silver . Richard T. . Goldman . John M. . Stone . Richard M. . Cervantes . Francisco . Hochhaus . Andreas . Powell . Bayard L. . Gabrilove . Janice L. . Rousselot . Philippe . 2006-12-07 . Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia . New England Journal of Medicine . en . 355 . 23 . 2408–2417 . 10.1056/NEJMoa062867 . 0028-4793. free . 17151364 .
  21. Web site: 2017-07-21 . CML Patients Approach Normal Life Expectancy With Imatinib Treatment . 2023-10-13 . Cancer Network . en.
  22. Printz . Carrie . 2017-05-15 . First person: Brian Druker, MD . Cancer . en . 123 . 10 . 1683–1684 . 10.1002/cncr.30753 . 0008-543X. free . 28475244 .
  23. News: Budnick. Nick. Top Oregon Health & Science University researcher to doctors: Rise up over drug prices. 2015-12-27. The Oregonian. Portland, Oregon. April 25, 2013.
  24. Web site: May 30, 2013 . The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts . 2023-10-13 . ashpublications.org.
  25. Web site: OHSU sets fundraising record by meeting $1 billion challenge from Nike co-founder and wife . 2023-10-13 . OHSU News . en.
  26. Web site: Bringing Precision Medicine to AML Patients Leukemia and Lymphoma Society . 2023-10-13 . www.lls.org.
  27. Web site: Tang Prize Laureates Brian J. Druker . 2023-10-13 . www.tang-prize.org . en.
  28. Web site: CLINICAL SCIENTIST AWARDS IN TRANSLATIONAL RESEARCH: Grant Recipients . Burroughs Wellcome Fund.
  29. Web site: Brupbacher Prize – Charles Rodolphe Brupbacher Foundation . 2023-10-13 . Charles Rodolphe Brupbacher Stiftung.
  30. Web site: Brian J. Druker, MD . 2023-10-13 . American Association for Cancer Research (AACR) . en.
  31. Web site: Prize Recipients Warren Alpert Foundation Prize . 2023-10-13 . warrenalpert.org.
  32. Web site: William Dameshek Prize Recipients . 2023-10-13 . www.hematology.org . en.
  33. Web site: OHSU researcher to get American Cancer Society medal . 2023-10-13 . Portland Business Journal.
  34. Web site: Robert Koch Award . 2023-10-13 . www.robert-koch-stiftung.de . en-en.
  35. Web site: Golden Plate Awardees of the American Academy of Achievement . www.achievement.org . American Academy of Achievement.
  36. Web site: Keio Medical Science Prize｜KEIO UNIVERSITY MEDICAL SCIENCE FUND . 2023-10-13 . www.ms-fund.keio.ac.jp.
  37. News: Williams . Elisa . February 22, 2011 . OHSU's Druker recognized for pioneering cancer research . . 2015-12-27.
  38. Web site: Ernest Beutler Lecture and Prize Recipients . 2023-10-13 . www.hematology.org . en.
  39. Web site: 2023-10-13 . www.dicksonprize.pitt.edu.
  40. Web site: UCSF Medal . 1 July 2020 . Office of the Chancellor . en.
  41. Web site: 2013-07-26 . OncLive Announces 2013 "Giants of Cancer Care" . 2023-10-13 . OncLive . en.
  42. Web site: Taubman Prize . 2023-10-13 . A. Alfred Taubman Medical Research Institute . en-US.
  43. Web site: Honorary Doctorates Erasmus University Rotterdam . 2023-10-13 . www.eur.nl . en.
  44. Web site: Prof. Brian J Druker - Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences - HMA . 2023-10-13 . www.hmaward.org.ae.
  45. Web site: 2019-11-23 . Professor Brian J. Druker . 2023-10-13 . Prince Mahidol Award Foundation . en-US.
  46. Web site: Rell Sunn 2019 - Druker and Hunter . 2023-10-13 . Luau & Legends of Surfing Invitational . en-US.
  47. Web site: Knight Cancer Institute at Oregon Health & Science University director named winner of Watanabe Prize, will deliver keynote address at virtual 2020 Indiana CTSI Annual Meeting . 2023-10-13 . Indiana CTSI . en-US.
  48. Web site: 2023 Drug Discovery Conference . 2023-10-13 . Stanford Cardiovascular Institute . sm.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Brian Druker".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.